Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing.

•Consolidative radiotherapy (RT) has been shown to improve overall survival in oligometastatic non-small cell lung cancer (NSCLC).•We quantified the costs of RT in oligometastatic NSCLC, by applying time-driven activity-based costing (TDABC).•This analysis uses TDABC to estimate the relative internal costs of various RT strategies associated with treating oligometastatic NSCLC.•This methodology will become increasingly relevant in context of the anticipated mandate of alternative/bundled payment models.